Docteur SYLVIE FABRE

Thèses universitaires

• Rémission de la polyarthrite rhumatoïde : apport des biomarqueurs et du mode d'administration des biothérapies

  2012

  Rheumatoid arthritis and remission : contribution of biomarkers and mode of biologics administration

  Biologie Santé🎓 Montpellier 1

  Direction : Christian Jorgensen, Florence Apparailly

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Bibliographie

• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

  2021

  ArticleThe Lancet Rheumatology

• Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

  2020

  ArticleAnnals of the Rheumatic Diseases

• Long-term corticosteroid use and dietary advice: a qualitative analysis of the difficulties encountered by patient

  2019

  ArticleBMC Health Services Research

• Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications

  2016

  ArticleTherapeutic advances in musculoskeletal disease

• Chest low-dose computed tomography for early lung cancer diagnosis as an opportunity to diagnose vertebral fractures in HIV-infected smokers, an ANRS EP48 HIV CHEST substudy

  2015

  ArticleJournal of Acquired Immune Deficiency Syndromes - JAIDS

• TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA

  2014

  ArticleJoint Bone Spine

• Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis

  2014

  ArticleMediators of Inflammation

• TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis

  2012

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Livres & ouvrages

• 📕

  Les huiles végétales

  Protéger - Nourrir - Régénérer

  2016 · 64 p.

• 📕

  L'approche infinie

  2002 · L'idée bleue · 95 p.

Source : Google Books — filtre catégories médicales/santé/sciences.

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• CL BEAU SOLEIL

  119 Avenue DE LODEVE, 34070 Montpellier

  ☎ 0467759999Hospitalier🏥 Voir cet établissement
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (3)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• "Avant, un K.O. ne voulait rien dire", Fulgence Ouedraogo témoigne au Lab Santé Midi Libre - Midi Libre

  📰 Midi Libre · 23/05/2024

  <a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPS0ZieDY3SlM0S2lNVzU4R0JuRGROd3lZMFZmMDVtNU91QkFKZFllVE0xdkV4V1hHSWcwVFNOMG5DWmE1d29VTXpod1Z4UjR1QnRnaUp5RnJaRElGaFg0OV9lR3pSRWxiaHF1akZQcHNSUnFRaER5R2lxdDNvemFaOUJ4bE5kREZMbGJQRU4xV0N0enlfVGgxUDFjRjA5VF9PNEtEZkc4S0h3QTQ1MW5ZMmk2enlxazJuSl

• La clinique Beau Soleil de Montpellier organise une journée de sensibilisation sur le rhumatisme inflammatoire - Midi Libre

  📰 Midi Libre · 21/09/2022

  <a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOYW9lcU5jaFQ5UnNJeEQzTWNwbFRTcjNmaE1BcmxyenlVWllmR29mT3dESE95Njh3LTRiaWZpQzhkTjdwQTdVcWhjcHc3TDFJdkt1S2pqcEJ6QVRmSFNxYV9ibnE0MjRLWFhDOUpWdFdfTWk5Nk1ieEFFb2hCSENIR3I2QlYta01PYUoyNlhqWEdIcVdCeFBmbGtyeTEyMDBTNng4TFA3LWpkRWYwbUYtV29FajRXbkZIdj

• Un programme d’éducation thérapeutique sur six mois - Midi Libre

  📰 Midi Libre · 26/09/2011

  <a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQWEtwWUlEMWY1eUdfSWpSblBQNmZQSEw2ZkZxWU02NUxuQ3BsTC05ZmtwSHpEa0dqWVhaOE1yT1EzdzhSMERHbUpKRnZYb3NHRHJXaDZUeTlvWTBrQXRmeWRUWW1BZEwtN3JQWjhNOXg4N0w5bzA3aUxlWG1GN3lBeHFSV1k5QjFnYm9yYm4xUHQ4a1N5bm5NakpsMk9lWXM?oc=5" target="_blank">Un programme

Top publications · les plus citées

• 1

  Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis

  Mediators of inflammation · 2014

  📚 81 citations🎯 RCR 2.82Top 18% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Although biologic therapies have changed the course of rheumatoid arthritis (RA), today’s major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our study aimed at quantifying miR-125b in blood and serum samples from RA patients, comparing healthy controls and patients with other forms of rheumatic diseases and arthritis, and evaluating its predictive value as biomarker for response to rituximab. Detectable levels of miR-125b were measured in total blood and serum samples and were significantly elevated in RA patients compared to osteoarthritic and healthy donors. The increase was however also found in patients with other forms of chronic inflammatory arthritis. Importantly, high serum levels of miR-125b at disease flare were associated with good clinical response to treatment with rituximab three months later (P=0.002). This predictive value was not limited to RA as it was also found in patients with B lymphomas. Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment.

• 2

  Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases

  Journal of clinical medicine · 2020

  📚 59 citations🎯 RCR 3.95Top 11% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  The Wnt pathway is a key element of bone remodeling; its activation stimulates bone formation and inhibits bone resorption. The discovery of sclerostin, a natural antagonist of the Wnt pathway, promoted the development of romosozumab, a human monoclonal antibody directed against sclerostin, as well as other anti-sclerostin antibodies. Phase 3 studies have shown the efficacy of romosozumab in the prevention of fractures in postmenopausal women, against placebo but also against alendronate or teriparatide and this treatment also allows bone mineral density (BMD) increase in men. Romosozumab induces the uncoupling of bone remodeling, leading to both an increase in bone formation and a decrease in bone resorption during the first months of treatment. The effect is attenuated over time and reversible when stopped but transition with anti-resorbing agents allows the maintenance or reinforcement of BMD improvements. Some concerns were raised about cardiovascular events. Therefore, romosozumab was recently approved in several countries for the treatment of severe osteoporosis in postmenopausal women with high fracture risk and without a history of heart attack, myocardial infarction or stroke. This review aims to outline the role of sclerostin, the efficacy and safety of anti-sclerostin therapies and in particular romosozumab and their place in therapeutic strategies against osteoporosis or other bone diseases.

• 3

  Erosive osteoarthritis of the hand: clinical experience with anakinra

  Annals of the rheumatic diseases · 2009

  📚 57 citations🎯 RCR 1.73

Publications scientifiques (34) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Long-term corticosteroid use and dietary advice: a qualitative analysis of the difficulties encountered by patient

  Collection2019Figshare

  Abstract Background Nearly 1% of the population is currently treated with long-term corticosteroid therapy. When corticosteroids are introduced, information concerning potential adverse effects and recommendations for li

• Long-term corticosteroid use and dietary advice: a qualitative analysis of the difficulties encountered by patient

  Collection2019Figshare

  Abstract Background Nearly 1% of the population is currently treated with long-term corticosteroid therapy. When corticosteroids are introduced, information concerning potential adverse effects and recommendations for li

• CFD modelling of flow distortion using OpenFOAM

  Dissertation2012University of Strathclyde

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche